DexCom appoints Renée Galá, Jazz Pharmaceuticals COO, to board

DEXCOM INC

Renée Galá appointed to DexCom board effective March 6, 2025; term expires at the 2025 annual meeting.
Galá currently serves as President and COO of Jazz Pharmaceuticals, with prior CFO roles at Jazz and Theravance Biopharma.
Received an initial RSU grant with a fair value of $500,000, vesting annually over three years.
Board determined Galá qualifies as an independent director under Nasdaq rules.
Galá also eligible for a pro-rated annual director RSU grant of $56,986 around the 2025 annual meeting.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Renée Galá

director

DXCM · DEXCOM INC

Effective: 2025-03-06
Filed: March 10, 2025, 7:59 PM ET

On March 6, 2025, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom”) increased the size of the Board to eleven directors and appointed Renée Galá as a director effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Renée Galá was appointed as director at DEXCOM INC.

Action: appointed
Role: director

Exact text from the filing

On March 6, 2025, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom”) increased the size of the Board to eleven directors and appointed Renée Galá as a director effective immediately.

View on SEC.gov

DEXCOM INC filing history →

Source: SEC EDGAR

accession 0001093557-25-000050

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.